Drug Search Results
More Filters [+]

Belapectin

Alternative Names: belapectin, gr-md-02, grmd02, gr md 02
Latest Update: 2024-11-19
Latest Update Note: Clinical Trial Update

Product Description

Belapectin (GR-MD-02) is a proprietary galactoarabino-rhamnogalacturonan polysaccharide polymer comprising galacturonic acid, galactose, arabinose, rhamnose and smaller amounts of other sugars. Structural studies have shown that belapectin binds to galectin-1 and galectin-3, with greater binding affinity to galectin-3. Belapectin targets extracellular galectins.

Mechanisms of Action: GAL3 Inhibitor

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Galectin
Company Location: NORCROSS GA 30071
Company CEO: Joel Lewis
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Belapectin

Countries in Clinic: Argentina, Australia, Belgium, Canada, Chile, France, Germany, Israel, Korea, Mexico, Poland, Puerto Rico, Spain, United Kingdom, United States

Active Clinical Trial Count: 4

Highest Development Phases

Phase 3: Esophageal and Gastric Varices|Fatty Liver, Alcoholic|Hepatitis, Alcoholic|Liver Cirrhosis|Liver Cirrhosis, Alcoholic|Non-alcoholic Steatohepatitis|Varicose Veins

Phase 1: Healthy Volunteers

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

GT-031

P3

Unknown Status

Liver Cirrhosis|Non-alcoholic Steatohepatitis

2028-01-14

NAVIGATE

P3

Active, not recruiting

Varicose Veins|Fatty Liver, Alcoholic|Non-alcoholic Steatohepatitis|Esophageal and Gastric Varices|Liver Cirrhosis, Alcoholic|Hepatitis, Alcoholic

2024-12-01

41%

NASH-RX

P3

Active, not recruiting

Liver Cirrhosis|Non-alcoholic Steatohepatitis

2023-09-11

GT-032

P1

Completed

Healthy Volunteers

2022-03-09

21%

Recent News Events